hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== Malformations === Esophageal strictures are usually benign and typically develop after a person has had reflux for many years. Other strictures may include esophageal webs (which can also be congenital) and damage to the esophagus by radiotherapy, corrosive ingestion, or eosinophilic esophagitis. A Schatzki ring is fibrosis at the gastroesophageal junction. Strictures may also develop in chronic anemia, and Plummer-Vinson syndrome. Two of the most common congenital malformations affecting the esophagus are an esophageal atresia where the esophagus ends in a blind sac instead of connecting to the stomach; and an esophageal fistula – an abnormal connection between the esophagus and the trachea. Both of these conditions usually occur together. These are found in about 1 in 3500 births. Half of these cases may be part of a syndrome where other abnormalities are also present, particularly of the heart or limbs. The other cases occur singly.
Concanavalin A (ConA) is a lectin (carbohydrate-binding protein) originally extracted from the jack-bean (Canavalia ensiformis). It is a member of the legume lectin family. It binds specifically to certain structures found in various sugars, glycoproteins, and glycolipids, mainly internal and nonreducing terminal α-D-mannosyl and α-D-glucosyl groups. Its physiological function in plants, however, is still unknown. ConA is a plant mitogen, and is known for its ability to stimulate mouse T-cell subsets giving rise to four functionally distinct T cell populations, including precursors to regulatory T cells; a subset of human suppressor T-cells is also sensitive to ConA. ConA was the first lectin to be available on a commercial basis, and is widely used in biology and biochemistry to characterize glycoproteins and other sugar-containing entities on the surface of various cells. It is also used to purify glycosylated macromolecules in lectin affinity chromatography, as well as to study immune regulation by various immune cells.
Liposomes, for instance, are small vesicles that can carry drugs and be modified to circulate longer or home in on specific brain regions. Dendrimers, with their tree-like structure, can hold multiple drug molecules and targeting agents at once. Polymeric nanoparticles, made from biodegradable materials like polylactic acid (PLA) or polylactic-co-glycolic acid (PLGA), can be engineered to release drugs over time in a controlled way. Solid lipid nanoparticles offer another alternative, combining biocompatibility with the ability to cross barriers more efficiently. Altogether, these advances are paving the way for more effective and precise treatments for a range of neurological disorders. Nanotechnology helps to transfer medicine to specific places in the body. Drug delivery in new forms with the assistance of minute particles, like liposomes or polymeric micelles. These particles support the drugs by preventing disintegration and enhancing functionality (Islam et al., 2025). An example would be, they can distribute cancer drugs to the tumors, which reduce the side effects. Researchers also come up with particles, which release drugs when going through certain conditions like heat or light. Despite the nature of this technology, it remains expensive and needs further safety studies. In the near future researchers say there will be a more advanced strategies of treatment such as the use nanomedicine and technology like artificial intelligence (Islam et al., 2025).
In 2005, the JECFA (Joint FAO/WHO Expert Committee On Food Additives) risk-assessment evaluation of ethyl carbamate concluded that the margin of exposure to ethyl carbamate from daily food and alcoholic beverages combined is of concern, and mitigation measures to reduce ethyl carbamate in some alcoholic beverages should continue. Ethyl carbamate exposure through alcoholic beverages has been discussed by multiple health authorities, while the cumulative daily exposure in the typical diet is also an issue of rising concern that merits closer observation. The Korean study concluded that "it would be desirable to closely monitor ethyl carbamate levels in Korean foods and find ways to reduce the daily intake." The following US regulators have mentioned urethane:
Sources: en.wikipedia.org
DiCaprio has mentioned growing up poor in a neighborhood plagued with prostitution, crime and violence. He was raised Catholic. DiCaprio attended the Los Angeles Center for Enriched Studies for four years and later Seeds Elementary School. He enrolled at John Marshall High School, but disliked public school and wanted to audition for acting jobs instead. He decided to drop out of high school, and later earned a general equivalency diploma (GED). As a child, DiCaprio wanted to become either an actor or a marine biologist. He chose to pursue acting because he enjoyed imitating people and impersonating characters, and liked seeing people's reactions to his impressions. According to DiCaprio, his interest in performing began at the age of two, when he went onstage at a performance festival and danced spontaneously to a positive response from the crowd. He was also motivated to learn acting when his stepbrother's appearance in a television commercial earned him $50,000. DiCaprio has said in interviews that his first television appearance was in the children's series Romper Room, and that he was dismissed from the show for being disruptive. The show's host has denied that any children were removed from the show in this way. At age 11, DiCaprio almost quit acting to pursue breakdancing, after winning second place in a breakdancing competition in his mother's native Germany. Starting at age 14, he appeared in several commercials for Matchbox cars, which he calls his first role. DiCaprio also appeared in commercials for Kraft Singles, Bubble Yum, and Apple Jacks.
Bleeding Infection Loss of grafted skin Nerve damage Graft-versus-host disease Marjolin's ulcer Rejection may occur in xenografts. To prevent this, the person receiving the graft usually must be treated with long-term immunosuppressant drugs.
=== Eye health === Nicotinamide has potential benefit in slowing vision loss and providing protection of eye cells, with the most promising evidence for protecting the retina from normal‑tension glaucoma and optic nerve from other forms of glaucoma. Relevant studies in the scientific literature speculate the mechanism of action to be direct retinal ganglion cell protection, among other indirect pathways in the optical nervous system. Contrary to nicotinamide, niacin has not been found to possess any properties in protecting optical nerve components as of 2026. Current research studies and American Academy of Ophthalmology have suggested a total daily intake of 1000mg, with optimal interval doses of 500mg spread throughout the day in promoting eye health.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.